S'abonner

Robot-Assisted Myomectomy versus Open Surgery : Cost-Effectiveness analysis : Cost-Effectiveness of Robotic Myomectomy - 19/12/24

Doi : 10.1016/j.jogoh.2024.102887 
Alexandre BOYER DE LATOUR 1, , Alexandra VAPPEREAU 2, Alicia LE BRAS 2, Amélia FAVIER 1, Martin KOSKAS 3, Bruno BORGHESE 4, Catherine UZAN 1, 5, 6, Isabelle DURAND-ZALESKI 2, 7, 8, #, Geoffroy CANLORBE 1, 5, 6, #,
1 Assistance Publique-Hospitals of Paris, Department of Gynecological and Breast Surgery and Oncology, Pitié Salpêtrière Hospital, Paris, France 
2 DRCI-URC Eco Ile-de-France (AP-HP), Public Assistance-Paris Hospitals, Paris, France 
3 Assistance Publique-Hospitals of Paris, Department of Gynecology and Obstetrics, Bichat Hospital, Paris, France and University Paris Cité 
4 Assistance Publique-Hospitals of Paris, Department of Gynecological Surgery, Cochin Hospital, Paris, France 
5 University Institute of Cancer (IUC), AP–HP, Sorbonne University, Paris, France 
6 Saint-Antoine Research Center (CRSA), INSERM UMR_S_938, Biology and Therapeutics of Cancer, Sorbonne University, Paris, France 
7 Public Assistance-Paris Hospitals, Public Health Service, Henri Mondor-Albert-Chenevier, Créteil, France 
8 CRESS, INSERM, INRA, University of Paris, Paris, France 

Corresponding Author: Alexandre Boyer de Latour and Geoffroy Canlorbe
Sous presse. Manuscrit accepté. Disponible en ligne depuis le Thursday 19 December 2024

Abstract

Introduction

Fibroids are the most common benign uterine tumors. There are different possibilities for surgical approaches, and evaluating the cost of these operations is fundamental in modern surgery. The aim of our study is to evaluate the cost-effectiveness of robotic-assisted myomectomy (RAM) compared to open myomectomy (OM) in France.

Materials and Methods

This is an original, retrospective cost analysis and cost-effectiveness comparison between RAM and OM. Women aged >18 years who had undergone myomectomy for large (>8 cm) or multiple (3-5) fibroids via RAM or OM were included from three French hospitals. Confounding factors were controlled using inverse probability of treatment weighting. Costs and major operative complications were assessed one month post-surgery for both groups. The cost per major operative complication (defined as intraoperative and/or postoperative transfusions and/or intraoperative blood loss ≥500 mL) averted was calculated. The incremental cost-effectiveness ratio was determined by dividing the difference in costs by the difference in complications. Uncertainty was explored through probabilistic and deterministic sensitivity analyses. Other complications were also compared between the two groups.

Results

33 womens were operate by RAM and 66 by OM. A statistically non-significant reduction in intraoperative and/or postoperative transfusions and/or intraoperative blood loss ≥ 500 mL will be in favor of RAM 36.19% RAM vs. 38.48% OM; p=0.85), with a difference of 2.29% [95% CI: -27.06% to 16.58%]. RAM was more expensive than OM, with an additional cost of €3,555 (P<0.01). The incremental cost-effectiveness ratio at one month was €155,241 per patient without complications. The intervention was 120 minutes shorter for OM (157) than RAM (277) (p<0,01). Readmissions were lower on RAM (0%) vs OM (1,21 %) (p <0,01) and the mean on length of stay was lower on RAM (2,90 days) vs OM (4,34 days) (p<0,01).

Conclusions

RAM reduced the length of hospitalization without increasing the risk of intraoperative complications compared to OM, making it a viable alternative. However, the economic evaluation within our hospitals did not favor RAM. Prospective studies with optimized RAM procedures are needed to confirm these results.

Le texte complet de cet article est disponible en PDF.

Keywords : cost-effectiveness, complications, robot-assisted myomectomy, surgery robotic, gynecology surgery, myomectomy

Abbreviations : ASA, BMI, CEROG, CI, CNGOF, CNIL, DRG, GBM, HUPS, ICER, LOS, OM, PMSI, RAM


Plan


 Formatting of funding sources : Surgery Intuitive participated in the English translation of this manuscript.


© 2024  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.